VOLLMERS ET AL. -- 10/579,107 Attorney Docket: 043043-0358637

## IN THE CLAIMS:

Please cancel claims 33, 36, 37 and 42 to 45 without prejudice. Please amend the claims and add new claims 89 to 96 as follows:

- 1. 20. (Cancelled)
- 21. (Currently Amended) A purified or isolated polypeptide antibody or a functional fragment thereof comprising a heavy chain variable region with at least 80% identity to the amino acid sequence of SEQ ID NO:5 [[or]] and a light chain variable region with at least 80% identity to the amino acid sequence of SEQ ID NO:7, and wherein the antibody or functional fragment thereof specifically binds to an adenocarcinoma of the colon, a diffuse-type stomach carcinoma, an adenocarcinoma of the pancreas, or an adenocarcinoma of the lung.
- 22. (Currently Amended) The purified or isolated polypeptide antibody or a functional fragment thereof of claim 21, wherein said polypeptide antibody or a functional fragment thereof comprises a heavy chain variable region with at least 85% identity to the amino acid sequence of SEO ID NO.5.
- 23. (Currently Amended) The purified or isolated polypeptide antibody or a functional fragment thereof of claim 22, wherein said polypeptide antibody or a functional fragment thereof comprises a light chain variable region with at least 85% identity to the amino acid sequence of SEQ ID NO:7.
  - 24. 26. (Cancelled)
- (Currently Amended) A purified or isolated polypeptide antibody or a functional fragment thereof comprising amino acids 31-35, 50-66, and 99-108 of SEQ ID NO:5 or amino acids 23-36, 52-58, and 91-101 of SEO ID NO:7.
- 28. (Currently Amended) The purified or isolated antibody or functional fragment of claim 27, wherein said polypeptide antibody or functional fragment thereof comprises amino acids 31-35, 50-66, and 99-108 of SEQ ID NO:5, and specifically binds to an adenocarcinoma of the colon, a diffuse-type stomach carcinoma, an adenocarcinoma of the pancreas, or an adenocarcinoma of the lung.
- (Currently Amended) The purified or isolated antibody or functional fragment of claim 27, wherein said antibody or functional fragment comprises amino acids 23-36, 52-58,

VOLLMERS ET AL. -- 10/579,107 Attorney Docket: 043043-0358637

- and 91-101 of SEQ ID NO:7, and specifically binds to an adenocarcinoma of the colon, a diffuse-type stomach carcinoma, an adenocarcinoma of the pancreas, or an adenocarcinoma of the lung.
- 30. (Currently Amended) The purified or isolated polypeptide antibody or functional fragment of claim 21 or claim 27 wherein said polypeptide is an antibody or [[a]] functional fragment thereof specifically binds to Colo-699 (DSMZ Accession Number ACC 196), CACO-2 (DSMZ Accession Number ACC 196), ATCC Accession Number HTB-37), 23132/87 (DSMZ Accession Number ACC 201), DU-145 (DSMZ Accession Number ACC 261, ATCC Accession Number ACC 298) cells.
- 31. (Currently Amended) The purified or isolated polypeptide antibody or functional fragment of claim [[30]] 21 or 27, wherein said antibody is a monoclonal antibody or a functional fragment thereof.
- 32. (Currently Amended) The purified or isolated polypeptide functional fragment of claim [[30]] 21 or 27, wherein said functional fragment is selected from the group consisting of V<sub>L</sub>, V<sub>H</sub>, F<sub>v</sub>, F<sub>e</sub>, Fab, Fab', and F(ab')<sub>2</sub>.
  - 33.-34. (Cancelled)
- 35. (Currently Amended) A functional fragment of an antibody, wherein said functional fragment The purified or isolated antibody or functional fragment of claim 21 or 27, eemprises comprising amino acids 31-35, 50-66, and 99-108 of SEQ ID NO:5 [[or]] and amino acids 23-36, 52-58, and 91-101 of SEQ ID NO:7.
  - 36. 46. (Cancelled)
- 47. (Currently Amended) The purified polypeptide or isolated antibody or functional fragment of any one of claims 21, 27, or 42, 21 or 27 wherein said polypeptide is also produced by the NORM-2 cell line having DSMZ deposit accession number DSM ACC2626.
  - 48. 88. (Cancelled)
- 89. (New) The purified or isolated antibody or functional fragment of claim 21 or claim 27 wherein said antibody or functional fragment comprises a heavy chain variable region at least 90% identical to SEO ID NO:5.

VOLLMERS ET AL. - 10/579,107 Attorney Docket: 043043-0358637

- 90. (New) The purified or isolated antibody or functional fragment of claim 21 or claim 27 wherein said antibody or functional fragment comprises a light chain variable region at least 90% identical to SEO ID NO:7.
- 91. (New) The purified or isolated antibody or functional fragment of claim 21 or claim 27 wherein said antibody or functional fragment comprises a heavy chain variable region at least 95% identical to SEO ID NO:5.
- 92. (New) The purified or isolated antibody or functional fragment of any one of claim 21 or claim 27, wherein said antibody or functional fragment comprises a light chain variable region at least 95% identical to SEO ID NO:7.
- 93. (New) The purified or isolated antibody or functional fragment of claim 21 or claim 27, wherein said antibody or functional fragment induces apoptosis of any one of Colo-699 (DSMZ Accession Number ACC 196), CACO-2 (DSMZ Accession Number ACC169, ATCC Accession Number HTB-37), 23132/87 (DSMZ Accession Number ACC 201), DU-145 (DSMZ Accession Number ACC 261, ATCC Accession Number HTB-81), or BM 1604 (DSMZ Accession Number ACC 298) cells.
- 94. (New) The purified or isolated antibody or functional fragment of claim 21 or claim 27, wherein said antibody or functional fragment decreases proliferation of any one of Colo-699 (DSMZ Accession Number ACC 196), CACO-2 (DSMZ Accession Number ACC 196), ATCC Accession Number HTB-37), 23132/87 (DSMZ Accession Number ACC 201), DU-145 (DSMZ Accession Number ACC 261, ATCC Accession Number HTB-81), or BM 1604 (DSMZ Accession Number ACC 298) cells.
- 95. (New) The purified or isolated antibody or functional fragment of claim 21 or claim 27, wherein the heavy or light chain variable region has an insertion, deletion or substitution of one amino acid residue.
- 96. (New) A purified or isolated antibody or a functional fragment thereof, wherein said antibody or functional fragment comprises the amino acid sequence of SEQ ID NO:5 and SEQ ID NO:7 with one amino acid insertion, deletion or substitution in either or both of SEO ID NO:5 and SEO ID NO:7.

4